H Robotics Smart Remote Rehabilitation Solution Rebless Wins CES 2021

H Robotics, a robot technology-based healthcare company, announced that it would officially enter the U.S. market by a partnership with the healthcare company Harmonic Bionics in the U.S. Under the partnership, H Robotics would supply the smart remote rehabilitation solution, “Rebless,” to Harmonic Bionics to treat patients with neurological and musculoskeletal disorders.

Patients using H Robotics’ Rebless could strengthen their muscles and perform rehabilitation exercises with a robot’s aid. Rebless features robot technology and IoT technology for its smart rehabilitation program and includes a device and a remote platform.

The robot device offers rehabilitation exercises on the elbow, ankle, wrist, and knee joints and provides rehabilitation exercises remotely. The data gathered from the activities get stored for diagnosis and future use through an application.

Exercise positions for the upper limbs using H Robotics Rebelss. (H Robotics)

Moreover, medical personnel could monitor and analyze a patient’s health status, together with the rehabilitation exercise performance history. Patients could also manage their rehabilitation exercises and schedules.

Innovation Award in the Healthcare & Wellness

The CES 2021 presented the Innovation Award in the Healthcare & Wellness category to recognize the product’s originality and innovation.

Exercise positions for the lower limbs using H Robotics Rebelss. (H Robotics)

The partnership with Harmonic Bionics ensures H Robotics’ plans to penetrate the U.S. medical market. Furthermore, H Robotics finished the registration of medical devices in the Food and Drug Administration in the second half of this year. The company also completed the registration of CPT insurance premium codes for rehabilitation exercises and telemedicine.

In the meantime, H Robotics fast-tracks the development of the global healthcare market after carrying out investments worth 6 billion won ($5.45 million). The Series A investments came from We Ventures, Schmidt, and CKD technology in November this year. Rebless received the Ministry of Food and Drug Safety certification, which marked its debut in the South Korean market.